Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02376868 · ClinicalTrials.gov registry record
Maestro Agreement and Precision Study II
A clinical trial, sponsored by Topcon Medical Systems.
- Completed
- Registry status
- 101
- Enrollment target
NCT02376868: Completed study, sponsored by Topcon Medical Systems.
NCT02376868 is a clinical trial that has completed, run by Topcon Medical Systems. The registered enrollment target is 101 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02376868 has completed, sponsored by Topcon Medical Systems.
- COMPLETED
- Registry status
- 101 participants
- Enrollment target
Study Summary
Assess the repeatability and agreement of the Optic Disc Parameters, Retinal Nerve Fiber Layer (RNFL) Thickness, Full Retinal Thickness, and Ganglion Cell Thickness between the Maestro and iVue OCT devices.
Primary Outcome
Reporting of the Optic Disc Size and Cup Size
Interventions
- DEVICE 3D OCT-1 Maestro
- DEVICE iVue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2015-05 |
| Est. Completion | 2015-09 |
What the finished NCT02376868 record still lists
NCT02376868 is an observational study that tracks outcomes without assigning an intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which 3D OCT-1 Maestro is the first listed.
NCT02376868 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02376868 about?
NCT02376868 is a clinical study titled "Maestro Agreement and Precision Study II". Assess the repeatability and agreement of the Optic Disc Parameters, Retinal Nerve Fiber Layer (RNFL) Thickness, Full Retinal Thickness, and Ganglion Cell Thickness between the Maestro and iVue OCT devices.
What is the current status of trial NCT02376868?
This trial is currently completed. The enrollment target is 101 participants. The study started on 2015-05. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02376868?
The interventions under investigation include: 3D OCT-1 Maestro (DEVICE), iVue (DEVICE).
Who is sponsoring clinical trial NCT02376868?
This trial is sponsored by Topcon Medical Systems, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia